Hepatotoxicity and Pediatric Liver Disorders Special Interest Groups Joint Symposium, Part 1. Drug-Induced Liver Injury: Drug-Induced Liver Injury Across the Lifespan—Advances in Management
Nov
09
2025
Convention Center: Room 202, Level 2
2:00 PM - 3:30 PM
Description
Topic experts discuss the risk of DILI and phenotypes of presentation from children to the elderly. Presenters review emerging and novel therapies associated with DILI, provide an update on blood-based biomarkers of DILI, and highlight research priorities to address knowledge gaps in this constantly evolving space.Journey Maps
Presentations
2:00 PM - 2:15 PM
Nov
09
2025
Washington, D.C.
Phenotypes of Drug-Induced Liver Injury: Overview of Drug-Induced Liver Injury in Children
Frank DiPaola, MD, Presenter
Drug-Induced Liver Injury
Pediatrics
2:15 PM - 2:30 PM
Nov
09
2025
Washington, D.C.
Drug-Induced Liver Injury During Pregnancy
Tatyana Kushner, MD, MSCE, Presenter
Drug-Induced Liver Injury
Pediatrics
2:30 PM - 2:45 PM
Nov
09
2025
Washington, D.C.
Drug-Induced Liver Injury in the Elderly
M Lucena, Presenter
Drug-Induced Liver Injury
Pediatrics
2:45 PM - 3:00 PM
Nov
09
2025
Washington, D.C.
Noninvasive Biomarkers in Drug-Induced Liver Injury: What Is Known and What Is New
Mitchell R McGill, PhD, Presenter
Drug-Induced Liver Injury
Pediatrics
Objectives
- Recognize the different phenotypes of DILI and the predominant culprit agents in children and adults.
- Identify the DILI risks associated with emerging and novel therapeutic agents.
- Devise strategies to mitigate the risks, diagnose, and manage DILI across the lifespan.
Chair
Lily Dara, MD
University of Southern California
Chair
Samar H Ibrahim, MBCHB, FAASLD
Mayo Clinic Rochester